The Prognostic Factor for Recurrence in Advanced-Stage High-Grade Serous Ovarian Cancer After Complete Clinical Remission: A Nested Case-Control Study
Qiao Wang(Sichuan University), Zhi‐Lan Peng(Sichuan University), Rutie Yin(Sichuan University), Ping Wang(Tianjin Medical University Cancer Institute and Hospital), Hui Liu(Sichuan University), Jiawen Zhang(Sichuan University), Hongling Peng(Central South University), Ce Bian(Sichuan University), Qingli Li(Sichuan University), Ying Zheng(Second People’s Hospital of Yibin)
Cited by 2
Related Papers
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆
|Annals of Oncology|2021|212
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer
|JAMA Oncology|2023|165
Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B
|Blood|2005|112
Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation
|Nature Communications|2018|91
Early Loss of Thrombomodulin Expression Impairs Vein Graft Thromboresistance
|Circulation Research|2002|74